Atara Biotherapeutics Inc

NASDAQ:ATRA  
15.00
+0.28 (+1.90%)
Earnings Announcements

Atara Biotherapeutics Reports Q1 Loss Per Share of $0.86

Published: 05/04/2021 20:09 GMT
Atara Biotherapeutics Inc (ATRA) - Q1 Loss per Share $0.86.
Atara Biotherapeutics- Cash, Cash Equivalents and Short-term Investments As of March 31 Totaled $435.2 Million, As Compared to $500.7 Million As of Dec 31.
Atara- Believes Its Cash As of March 31, 2021 Together With Projected Revenue From U.S. Tab-cel Sales is Sufficient to Fund Its Operations Into 2023.
License and Collaboration Revenue Was $3.6 Million for Q1 2021.
Net Cash Used in Operating Activities Was $65.7 Million for Q1 2021.
Atara Reported Net Losses of $78.3 Million, Or $0.86 per Share, for Q1 2021.
Revenue is expected to be $3.71 Million
Adjusted EPS is expected to be -$0.90

Next Quarter Revenue Guidance is expected to be $3.71 Million
Next Quarter EPS Guidance is expected to be -$0.89

More details on our Analysts Page.